Voluntary nationwide recall: Systane (Alcon – December)

Jan. 2025Pharmacy Updates

Alcon Laboratories is recalling one lot, lot 10101, of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go. Systane Lubricant Eye Drops. Ultra PF is used for the temporary relief of burning and irritation in persons with dry eye symptoms.

This drug is being recalled because Alcon evaluated a consumer complaint of foreign material observed inside a sealed single-use vial and determined the material to be fungal in nature. Using an eye product that contains fungal material may cause eye infections. These eye infections could be vision-threatening or life-threatening in people with weakened immune systems.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Systane, you should stop using the product and return it to the place of purchase for a replacement or refund.

As of Dec. 23, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Alcon Laboratories at 1-800-241-5999. TTY users should call 711. Help is available Monday through Friday from 7:30 a.m. to 6 p.m. CST.
  • Visit the FDA website.

Recent Announcements

Access member care plans in UPMC Health Plan Tapestry Link

Starting Dec. 1, 2026, providers will be able to access SNP care plans within UPMC Health Plan Tapestry Link. Care plans are visible on a member’s chart in multiple locations:
Nov. 2026Important Notices

UPMC Health Plan Tapestry Link resources available

UPMC Health Plan Tapestry Link will launch on Tuesday, Dec. 1, 2026. To help ease your transition to the new platform, we have developed the following resources:
Nov. 2026Important Notices

Changes to inpatient denial and OBS claim billing

We will soon transition to the Epic® platform. This change will align our claims processing with industry standards by adjudicating claims based on the level of care authorized. As this transition approaches, please keep the following areas in mind:
Nov. 2026